Literature DB >> 19107233

Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis.

Zhong Wu1, HyungJun Cho, Garret M Hampton, Dan Theodorescu.   

Abstract

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is frequently inactivated in metastatic prostate cancer, yet the molecular consequences of this and their association with the metastatic phenotype are incompletely understood. We performed transcriptomic analysis and identified genes altered by conditional PTEN reexpression in C4-2, a human metastatic prostate cancer cell line with inactive PTEN. PTEN-regulated genes were disproportionately represented among genes altered in human prostate cancer progression and metastasis but not among those associated with tumorigenesis. From the former set, we identified two novel putative PTEN targets, cdc6 and cyclin E2, which were overexpressed in metastatic human prostate cancer and up-regulated as a function of PTEN depletion in poorly metastatic DU145 human prostate cancer cells harboring a wild type PTEN. Inhibition of cdc6 and cyclin E2 levels as a consequence of PTEN expression was associated with cell cycle G(1) arrest, whereas use of PTEN activity mutants revealed that regulation of these genes was dependent on PTEN lipid phosphatase activity. Computational and promoter-reporter evaluations implicated the E2F transcription factor in PTEN regulation of cdc6 and cyclin E2 expression. Our results suggest a hypothetical model whereby PTEN loss upregulates cell cycle genes such as cdc6 and cyclin E2 that in turn promote metastatic colonization at distant sites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19107233      PMCID: PMC2606120          DOI: 10.1593/neo.81048

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  40 in total

1.  Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.

Authors:  Deborah DeFeo-Jones; Stanley F Barnett; Sheng Fu; Paula J Hancock; Kathleen M Haskell; Karen R Leander; Elizabeth McAvoy; Ronald G Robinson; Mark E Duggan; Craig W Lindsley; Zhijian Zhao; Hans E Huber; Raymond E Jones
Journal:  Mol Cancer Ther       Date:  2005-02       Impact factor: 6.261

2.  PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells.

Authors:  D M Li; H Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

Authors:  Andrea H Bild; Guang Yao; Jeffrey T Chang; Quanli Wang; Anil Potti; Dawn Chasse; Mary-Beth Joshi; David Harpole; Johnathan M Lancaster; Andrew Berchuck; John A Olson; Jeffrey R Marks; Holly K Dressman; Mike West; Joseph R Nevins
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

4.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

5.  PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.

Authors:  Denggao Yao; Claire L Alexander; Jean A Quinn; Michael J Porter; Hong Wu; David A Greenhalgh
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

6.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.

Authors:  H Suzuki; D Freije; D R Nusskern; K Okami; P Cairns; D Sidransky; W B Isaacs; G S Bova
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

7.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

Authors:  M E McMenamin; P Soung; S Perera; I Kaplan; M Loda; W R Sellers
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

8.  Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells.

Authors:  Setsuko Mise-Omata; Yuichi Obata; Shigeru Iwase; Nathan Mise; Takahiro S Doi
Journal:  Biochem Biophys Res Commun       Date:  2005-03-25       Impact factor: 3.575

9.  Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells.

Authors:  Z Yan; J DeGregori; R Shohet; G Leone; B Stillman; J R Nevins; R S Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

10.  Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers.

Authors:  J M Gudas; M Payton; S Thukral; E Chen; M Bass; M O Robinson; S Coats
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

View more
  24 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.

Authors:  Mahandranauth A Chetram; Valerie Odero-Marah; Cimona V Hinton
Journal:  Mol Cancer Res       Date:  2010-11-12       Impact factor: 5.852

3.  Estimation of High-Dimensional Graphical Models Using Regularized Score Matching.

Authors:  Lina Lin; Mathias Drton; Ali Shojaie
Journal:  Electron J Stat       Date:  2016-04-06       Impact factor: 1.125

4.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

5.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  Mice lacking β-carotene-15,15'-dioxygenase exhibit reduced serum testosterone, prostatic androgen receptor signaling, and prostatic cellular proliferation.

Authors:  Joshua W Smith; Nikki A Ford; Jennifer M Thomas-Ahner; Nancy E Moran; Eric C Bolton; Matthew A Wallig; Steven K Clinton; John W Erdman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

7.  Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.

Authors:  C Elizabeth Caldon; Elizabeth A Musgrove
Journal:  Cell Div       Date:  2010-01-17       Impact factor: 5.130

8.  Expression of AKAP95, Cx43, CyclinE1 and CyclinD1 in esophageal cancer and their association with the clinical and pathological parameters.

Authors:  Shupeng Zhao; Min Yi; Yangyang Yuan; Wenxin Zhuang; Dengcheng Zhang; Xiuyi Yu; Xiaoxuan Chen; Bogang Teng; Zhiyu Guan; Yongxing Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

9.  An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.

Authors:  Xiaolu Pan; Xuemin Lu; Xin Lu; Chang-Jiun Wu; Di Zhao; Shan Feng; Yong Zang; Rumi Lee; Sunada Khadka; Samirkumar B Amin; Eun-Jung Jin; Xiaoying Shang; Pingna Deng; Yanting Luo; William R Morgenlander; Jacqueline Weinrich; Shan Jiang; Qing Chang; Nora M Navone; Patricia Troncoso; Ronald A DePinho; Y Alan Wang
Journal:  Cancer Res       Date:  2018-05-16       Impact factor: 12.701

Review 10.  Molecular imaging of prostate cancer: a concise synopsis.

Authors:  Hossein Jadvar
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.